The fusion-active conformation of the envelope protein gp41 of HIV-1 consists of an N-terminal trimeric alpha-helical coiled coil domain, and three anti-parallel C-terminal helices which fold down the grooves of the coiled coil to form a six-helix bundle. Disruption of the six-helix bundle is considered to be a key component of an effective non-peptide fusion inhibitor. This structure forms as a result of a conformational change in gp41, triggered by gp120 and co-receptor binding to host cell receptors. Prevention of six-helix bundle formation has been recognized as an important mechanism for viral fusion inhibition A metallopeptide-based fluorescence assay has been developed to detect HIV-1 fusion inhibitors, by the screening of small molecules that bind to the hydrophobic pocket of gp41. The assay involves two peptides representing the inner N-terminal-heptad-repeat (HR1) coiled coil and the outer C-terminal-heptad-repeat (HR2) helical domains of the gp41 six-helix bundle which forms prior to fusion. The HR1 peptide is modified with a metal-ligated dye complex, which maintains structural integrity and permits association with a fluorescein-labeled HR2 peptide concomitant with fluorescence quenching. Compounds able to disrupt six-helix bundle formation can act as fusion inhibitors, and can be detected in the assay from an increase in the fluorescence that is correlated with compound's efficacy. Primary, single concentration screen: Assay materials: 1) Env2.0 peptide Seq: Ac-MTWBEWDREIBNYTSLIC(FAM)-NH2 2) C18-Aib(FL) peptide Seq: bpy-GQAVEAQQHLLQLTVWGIKQLQARILAVEKK-NH2 3) Assay Buffer: 25 mM Tris-acetate pH 7.0, 0.01% Tween-20 4) The Fe(II) complex [Fe(II)(env2.0)3]2+ is prepared by addition of a one-third stoichiometry of freshly prepared ferrous ammonium sulfate to peptide in 25 mM Tris-acetate pH 7.0 Procedure Mix equal parts of the Env2.0/Fe complex and C18-Aib(FL) (60 uM) just prior to the assay 1) Dispense 4 ul of 60 uM C18-Aib(FL) into columns 1 and 2 of a black, Corning (#2725) 1536 well assay plate. 2) Add 4 ul of 60 uM C18-Aib(FL)/4 uM Env2.0/Fe complex into columns 3-48 3) Using a HighRes biosolutions pintool dispense 40 nl of 2 mM compounds in DMSO to columns 5-48 4) Using a HighRes biosolutions pintool dispense 40 nl of DMSO to columns 1-4. 5) Incubate lidded plate for 30 minutes at room temp. 6) Read plate on a BMG PHERAstar at 485/520nm in Fluorescence Intensity mode Positioning delay = 0.0 Flashes/well = 10 Dose Response: Assay materials: 5) Env2.0 peptide Seq: Ac-MTWBEWDREIBNYTSLIC(FAM)-NH2 6) C18-Aib(FL) peptide Seq: bpy-GQAVEAQQHLLQLTVWGIKQLQARILAVEKK-NH2 7) Assay Buffer: 25 mM Tris-acetate pH 7.0, 0.01% Tween-20 8) The Fe(II) complex [Fe(II)(env2.0)3]2+ is prepared by addition of a one-third stoichiometry of freshly prepared ferrous ammonium sulfate to peptide in 25 mM Tris-acetate pH 7.0 Procedure 1) Using a Labcyte Echo, DMSO and test compounds are transferred to wells of a black, Corning 1536 well assay plate. DMSO only is transferred to columns 1-3 and 46-48(Control wells), while varying volumes of test compounds are transferred to columns 4-45 to achieve the desired test concentrations. Compounds are transferred from a 2 mM stock to give the stated final concentration. Test compound wells in the assay plate are back-filled with DMSO to equalize final assay concentrations. 2) Immediately following Echo Transfer, 2 ul of assay buffer is added to columns 1 and 2. 3) Add 2 ul of 60 uM C18-Aib(FL) into columns  3-48 of a black, Corning (#2725) 1536 well assay plate. 4) Add 2 ul of 4 uM Env2.0/Fe complex into all columns (1-48) 5) Incubate lidded plate for 30 minutes at room temp. 6) Read plate on a BMG PHERAstar at 485/520nm in Fluorescence Intensity mode i. Positioning delay = 0.0 ii. Flashes/well = 10
bao:BAO_0001067 "1986_2" ; # "is primary assay of" -> "1986_2"
bao:BAO_0001067 "2279" ; # "is primary assay of" -> "2279"
bao:BAO_0000812 "1991" ; # "has summary assay" -> "1991"
bao:BAO_0000808 bao:BAO_0000031 ; # "has primary assay" -> "primary assay"
bao:BAO_0000205 bao:BAO_0000217 ; # "has assay format" -> "biochemical format"
bao:BAO_0000205 bao:BAO_0000224 ; # "has assay format" -> "protein format"
bao:BAO_0000205 bao:BAO_0000357 ; # "has assay format" -> "single protein format"
bao:BAO_0000409 bao:BAO_0000410 ; # "assay measurement type" -> "endpoint assay"
bao:BAO_0002850 bao:BAO_0000534 ; # "has assay readout content" -> "single readout"
bao:BAO_0002851 "single parameter" ; # "has assay readout content parametricity" -> "single parameter"
bao:BA0_0090012 bao:BAO_0000392 ; # "has participant" -> "generic membrane protein" || bao:BAO_0003102 bao:BAO_00020144 ; # "has role" -> "target"
bao:BAO_0002855 bao:BAO_0000110 ; # "is bioassay type of" -> "protein-small molecule interaction assay"
bao:BAO_0000212 bao:BAO_0000123 ; # "has assay method" -> "binding assessment method"
bao:BAO_0000207 bao:BAO_0000363 ; # "has detection method" -> "fluorescence intensity"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Identification of human immunodeficiency virus fusion inhibitors" ; # "screening campaign name" -> "Identification of human immunodeficiency virus fusion inhibitors"
bao:BAO_0002853 "uHTS fluorescence assay for the identification of Human Immunodeficiency Virus Fusion Inhibitors." ; # "has assay title" -> "uHTS fluorescence assay for the identification of Human Immunodeficiency Virus Fusion Inhibitors."
bao:BAO_0003105 <http://purl.obolibrary.org/obo/GO_0005488> ; # "has function" -> "binding"
bao:BAO_0002867 bao:BAO_0000516 ; # "has assay footprint" -> "1536 well plate"
bao:BAO_0002863 bao:BAO_0000536 ; # "has concentration throughput" -> "single concentration"
bao:BAO_0000109 "25 degree celsius" ; # "has temperature value" -> "25 degree celsius"
bao:BAO_0002833 "30 minute" ; # "has incubation time value" -> "30 minute"
bao:BA0_0090012 bao:BAO_0000118 ; # "has participant" -> "DMSO"
bao:BAO_0000740 bao:BAO_0000079 ; # "has assay control" -> "negative control"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Miriam Gochin" ; # "material entity assay provider" -> "Miriam Gochin" || bao:BAO_0003102 bao:BAO_0000027 ; # "has role" -> "assay provider"
bao:BAO_0002020 bao:BAO_0000372 ; # "has assay phase characteristic" -> "homogeneous phase"
bao:BA0_0090012 bao:BAO_0000694 ; # "has participant" -> "Tris" || bao:BAO_0003102 <http://purl.obolibrary.org/obo/CHEBI_35225> ; # "has role" -> "buffer"
bao:BA0_0090012 bao:BAO_0001038 ; # "has participant" -> "Tween 20" || bao:BAO_0003102 <http://purl.obolibrary.org/obo/CHEBI_27780> ; # "has role" -> "detergent"
bao:BA0_0090012 "Envelope glycoprotein gp160" ; # "has participant" -> "Envelope glycoprotein gp160"
bao:BAO_0002921 <http://purl.obolibrary.org/obo/NCBITaxon_11676> ; # "has organism" -> "Human immunodeficiency virus 1"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Q9DVL6" ; # "uniprot ID" -> "Q9DVL6"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "11676" ; # "NCBI taxonomy ID" -> "11676"
bao:BAO_0002662 bao:BAO_0000644 ; # "has quality" -> "truncated"
bao:BAO_0002897 bao:BAO_0000360 ; # "has preparation method" -> "recombinant expression"
bao:BA0_0090012 "Fluorescein" ; # "has participant" -> "Fluorescein"
bao:BAO_0002000 bao:BAO_0002001 ; # "has measured entity" -> "measured entity"
bao:BAO_0002857 bao:BAO_0000261 ; # "has signal direction" -> "signal decrease corresponding to inhibition"
bao:BA0_0090012 bao:BAO_0000176 ; # "has participant" -> "small molecule" || bao:BAO_0003102 bao:BAO_00020137 ; # "has role" -> "perturbagen"
bao:BAO_0000212 bao:BAO_0000574 ; # "has assay method" -> "single perturbagen"
bao:BAO_0002865 bao:BAO_0000705 ; # "uses detection instrument" -> "PHERAstar Plus"
bao:BAO_0000737 bao:BAO_0000863 ; # "has manufacturer" -> "BMG Labtech" || bao:BAO_0003102 bao:BAO_0002628 ; # "has role" -> "instrumentation manufacturer"
bao:BAO_0002917 "485 nanometer" ; # "has excitation wavelength value" -> "485 nanometer"
bao:BAO_0002918 "520 nanometer" ; # "has emission wavelength value" -> "520 nanometer"
bao:BAO_0000337 bao:BAO_0000201 ; # "has percent response" -> "percent inhibition"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "5" ; # "PubChem TID" -> "5"
bao:BAO_0000182 <http://purl.org/obo/owl/UO#UO_0000187> ; # "has response unit" -> "percent"
bao:BAO_0002666 "20" ; # "has concentration value" -> "20"
bao:BAO_0000183 <http://purl.org/obo/owl/UO#UO_0000064> ; # "has concentration unit" -> "micromolar"
bao:BAO_0002787 "1" ; # "has concentration-point number" -> "1"
bao:BAO_0002845 "2" ; # "has repetition point-number" -> "2"
bao:BAO_0000196 bao:BAO_0000091 ; # "has mode of action" -> "inhibition"
bao:BAO_0002864 bao:BAO_0000533 ; # "has repetition throughput" -> "multiple repetition"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "kunie-2" ; # "Annotated by" -> "kunie-2"
bao:BAO_0000540 "1986_1" ; # "is confirmatory assay of" -> "1986_1"
bao:BAO_0000809 bao:BAO_0000030 ; # "has confirmatory assay" -> "confirmatory assay"
bao:BAO_0000208 bao:BAO_0000190 ; # "has endpoint" -> "IC50"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "2" ; # "PubChem TID" -> "2"
